Swisscare Pharmasp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2014-03-25
Share capital
90,000.00 PLN
Registered address
ul. Jarosława Iwaszkiewicza 37, 82-300 Elbląg, Poland

Financials

Revenue history (in k)

Filing timeliness

5 of 6 financial statements were filed late (the longest delay 214 days for 2024).

  • 202530/03/2026
  • 202414/02/2026
  • 202324/10/2024
  • 202231/01/2024
  • 202126/09/2022
  • 202008/11/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 111.79kMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD 18.93kMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 90.60kMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 612.58kMedianUSD 608.93kAverageUSD 11.85m

Trademarks

Swisscare Pharma holds 1 active trademark registered with the Polish Patent Office. 1 application is pending. 1 mark has expired or was not registered. The first mark was filed in 2011.

MarkNumberClassesStatusProtected until
SwissCare PharmaZ.38251335, 44Protected Mar 10, 2031
SwissCareZ.6011315Application pending –
SwissCareZ.5961935Proceedings discontinued –
MarkProtected until
SwissCare PharmaMar 10, 2031
SwissCare–
SwissCare–

Authorized Representatives

Beata Albertowicz Klikiewicz – Management Board Member
Michał Paweł Klikiewicz – President of the Management Board

Manner of representation

One-person representation.

Ownership

OwnerSharesShare valueStake
Beata Agata Albertowicz Klikiewiczage 54
1,799$24,297.6899.9444%
Others
1$13.510.0556%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2014-01-31.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,282

Competitors

Name
OwlieS.A.
Integris Medical Polskasp. z o.o.
Geneco Groupsp. z o.o.
Black & Whitesp. z o.o.
BL Medicasp. z o.o.
Screenmedsp. z o.o.
Pharmbiopolsp. z o.o.
Mimic Polandsp. z o.o.
Osteoprofsp. z o.o.
Toto Pharma Polandsp. z o.o.

Change history

DateEvent
2020-01-15PKD change
2016-05-17Address change
2014-03-25Entered in the register

FAQ

Last updated: 2026-10-07